Global Drug Facility: Provision of Anti-Tuberculosis Drugs

Reporting Organization:UNOPS - United Nations Office for Project Services
Total Budget ($CAD):$ 37,121,095
Timeframe: March 20, 2010 - February 11, 2020
Status: Completion
Contact Information: Unspecified

Partner & Funder Profiles

Reporting Organization

UNOPS - United Nations Office for Project Services

Participating Organizations


Funders (Total Budget Contribution)

Return to top


Region - Total Budget Allocation

Sub-Saharan Africa - $ 11,433,297.26 (30.80%)

Southeast Asia - $ 7,535,582.29 (20.30%)

South Asia - $ 6,162,101.77 (16.60%)

East Asia - $ 5,531,043.16 (14.90%)

Central Asia - $ 3,415,140.74 (9.20%)

North Africa - $ 1,559,085.99 (4.20%)

Europe - $ 1,113,632.85 (3.00%)

South America - $ 259,847.67 (0.70%)

Central America - $ 111,363.29 (0.30%)

Return to top

Areas of Focus

Health - Total Budget Allocation

Infectious & Communicable Diseases (100 %)

Return to top


This grant represents part of Canada’s contribution to the Global Drug Facility (GDF), a program of the Stop TB Partnership. It provides access to anti-tuberculosis (TB) drugs for governments that agree to introduce, expand, or maintain the diagnostic, treatment, and monitoring policies of the DOTS (directly observed treatment, short-term) strategy. Launched in 2001, the GDF works to improve the supply, distribution, and monitoring of anti-TB drugs in developing countries and is the only global bulk procurer of anti-TB drugs. Canada was the founding donor of the GDF and to date (2010) has been the single largest donor country for first-line TB drugs. The GDF is a four-pronged mechanism whereby: (1) countries who cannot afford to procure all the anti-TB drug they need are eligible to apply for drugs for up to six years (DFATD provides funding for this component); (2) countries who can pay for the anti-TB drugs they need but cannot assure the quality of the drugs can directly procure them through the GDF at reduced bulk prices (DFATD funding does not contribute to this component); (3) countries where the procurement system is weak can receive technical assistance to strengthen their capacity for drug procurement (DFATD supports this component); and (4) Global Fund recipient countries can procure anti-TB drugs directly through GDF, using Global Fund monies, to ensure a stable and high-quality drug supply.

Return to top

Target Population

Gender and age: Adult women Adult men Adolescent females Adolescent males Children, girls Children, boys Under-5 children Newborns Older adults, women Older adults, men
Total Direct Population: Unspecified
Return to top



Return to top

Results & Indicators

Expected Results


Achieved Results

Results achieved by Global Drug Facility, through the support of the Government of Canada and other international donors, as of March 2016 include: (1) provided quality-assured treatments since 2001 for more than 27 million patients with tuberculosis (TB), This included over 184,000 patient treatments for multi-drug resistant TB (MDR-TB) and 1.5 million treatments for children; (2) delivered over 1.5 million patient treatments, including over 219,000 pediatric treatments in 2015; (3) provided capacity-building support to 134 countries since 2001, including training and workshops, monitoring missions and technical assistance to improve the management of drug supplies; (4) contributed to planning and guidance for the global introduction of new child-friendly medicines for pediatric TB; and (5) provided a mechanism for countries to order the new pediatric formulations and made grants available to eligible countries to purchase pediatric TB medicines with funding from Global Affairs Canada.


  • None Selected
Return to top
Return to top

Associated Projects (If applicable)

Return to top